Edition:
United Kingdom

Zosano Pharma Corp (ZSAN.OQ)

ZSAN.OQ on NASDAQ Stock Exchange Capital Market

4.14USD
9:00pm BST
Change (% chg)

$-0.20 (-4.61%)
Prev Close
$4.34
Open
$4.33
Day's High
$4.34
Day's Low
$4.14
Volume
38,273
Avg. Vol
213,294
52-wk High
$27.70
52-wk Low
$3.63

Latest Key Developments (Source: Significant Developments)

Zosano Pharma Q1 Loss Per Share $4.16
Tuesday, 15 May 2018 

May 15 (Reuters) - Zosano Pharma Corp ::ZOSANO PHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL UPDATE.Q1 LOSS PER SHARE $4.16.  Full Article

Adage Capital Partners GP LLC Reports 8.35 Pct Passive Stake In Zosano Pharma Corp
Friday, 6 Apr 2018 

April 6 (Reuters) - Adage Capital Partners GP, L.L.C.::ADAGE CAPITAL PARTNERS GP, L.L.C. REPORTS 8.35 PCT PASSIVE STAKE IN ZOSANO PHARMA CORP AS OF MARCH 29 - SEC FILING.  Full Article

Zosano Pharma Files For Offering Of Up To $57.5 Million Shares
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Zosano Pharma Corp ::ZOSANO PHARMA FILES FOR OFFERING OF UP TO $57.5 MILLION SHARES - SEC FILING.  Full Article

Zosano Announces Resignation Of Bruce Steel From Board
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Zosano Pharma Corp ::ZOSANO ANNOUNCES RESIGNATION OF BRUCE STEEL FROM BOARD OF DIRECTORS.ZOSANO PHARMA CORP - FOLLOWING STEEL'S RESIGNATION, NUMBER OF BOARD OF DIRECTOR SEATS HAS BEEN REDUCED TO FIVE.  Full Article

Zosano pharma Q3 loss per share $0.20
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Zosano Pharma Corp ::Zosano pharma reports third quarter 2017 financial results and operational update.Q3 loss per share $0.20.  Full Article

Zosano Pharma Corp says sold upto $7.5 mln in equity and other financing
Monday, 29 Aug 2016 

Zosano Pharma Corp :Sold upto $7.5 million in equity and other financing -SEC Filing.  Full Article

Zosano Pharma says expect to enroll 360 subjects at approximately 35 centers across United States for trial
Wednesday, 10 Aug 2016 

Zosano Pharma Corp : Q2 loss per share $0.54 . Zosano Pharma reports second quarter 2016 financial results . Says remain on track to report data in q1 2017 in m207 efficacy trial for acute migraine .Says expect to enroll three hundred and sixty subjects at approximately 35 centers across united states for trial.  Full Article

BRIEF-Adage Capital Partners GP LLC Reports 8.35 Pct Passive Stake In Zosano Pharma Corp

* ADAGE CAPITAL PARTNERS GP, L.L.C. REPORTS 8.35 PCT PASSIVE STAKE IN ZOSANO PHARMA CORP AS OF MARCH 29 - SEC FILING Source text: (http://bit.ly/2Hh8YE8) Further company coverage: